发明名称 |
Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (R-Spondins) and/or Wnt |
摘要 |
The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. |
申请公布号 |
US8921056(B2) |
申请公布日期 |
2014.12.30 |
申请号 |
US201414245807 |
申请日期 |
2014.04.04 |
申请人 |
Deutsches Krebsforschungszentrum |
发明人 |
Niehrs Christof;Wu Wei;Glinka Andrey;Kazanskaya Olga |
分类号 |
C12Q1/68;C12Q1/66;C12N9/00 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
Yonker Stephanie |
主权项 |
1. A method of determining whether a binding partner of a Futrin 1 polypeptide affects Wnt signaling activity, the method comprising:
(a) providing a mammalian cell in culture comprising the Futrin 1 polypeptide and a Wnt inducible reporter, wherein the Futrin 1 polypeptide comprises the amino acid sequence of SEQ ID NO:26, the amino acid sequence of amino acids 21-243 of SEQ ID NO:26, the amino acid sequence of amino acids 1-146 of SEQ ID NO:26, or the amino acid sequence of amino acids 21-146 of SEQ ID NO:26, wherein the Futrin 1 polypeptide is able to promote Wnt signaling; and (b) detecting the level of reporter expression in the cell in the presence and absence of the binding partner, wherein a change in the level of reporter expression indicates that the binding partner affects the Wnt signaling. |
地址 |
Heidelberg DE |